Navigation Links
HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference
Date:11/18/2010

FRAMINGHAM, Mass. and SYDNEY, Nov. 18, 2010 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR) (ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the 22nd Annual Piper Jaffray Health Care Conference on Tuesday, November 30, at 3:00 pm EST.  The conference is being held November 30 – December 1, 2010 at the New York Palace in New York City.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  An archived replay of the presentation will also be available shortly after the presentation time for a period of 90 days.

About HeartWare InternationalHeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securi
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. HeartWare International, Inc. Temporary Suspension of Trading
2. U.S. Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International
3. Ridge Diagnostics, Inc. Presents Clinical Data on Blood Test for Depression at U.S. Psychiatric and Mental Health Congress
4. Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany
5. Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
6. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
7. Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany
8. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
9. China Biologic Products to Present at Brean Murray, Carret 2010 China Growth Conference
10. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
11. Ardea Biosciences to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer health ... EmblemHealth , the New York -based ... RedBrick Compass health assessment, combined with the RedBrick Journeys ... EmblemHealth is among the first health plans in the ...
(Date:1/15/2014)... January 15, 2014 More than 5 ... about 1 in 3 seniors will die with Alzheimer’s ... These jaw-dropping figures have shocked many Americans into looking ... help prevent these tragic age-related cognitive disorders. Jonathan Weisman, ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2DTS Improves Efficiency for Life Science Document Translations 2
... March 12 Medivation, Inc. (Nasdaq: MDVN ) today announced that it will host a ... business update on March 15, 2010 , at 4:30 p.m. Eastern Time . A press release ... close on March 15, 2010 . , ... ...
... Elan Pharmaceuticals, Inc. (a subsidiary of Elan Corporation, plc) ( ELN) ("Elan") to acquire the analgesic therapy, PRIALT(R) (ziconotide intrathecal infusion). , ... , ... ... ...
... CHICAGO , March 11 Advanced Life ... company engaged in the discovery, development and commercialization of ... and respiratory diseases, announced today that the U.S. Food ... clinical program required to assess the approvability of Restanza™ ...
Cached Biology Technology:Medivation Announces Fourth Quarter and Year-End 2009 Financial Results Teleconference and Webcast On March 15, 2010 2Medivation Announces Fourth Quarter and Year-End 2009 Financial Results Teleconference and Webcast On March 15, 2010 3Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 2Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 3Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 4Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 5Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 6Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 2Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 3Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 4Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 5Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 6Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 7Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 8Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications 9
(Date:4/23/2014)... ravens form different types of social relationships they ... form strict dominance relations. From a cognitive perspective, understanding ... in daily social life ("knowing who is nice or ... with each other sets the stage for "political" maneuvers ... study have been published in the scientific journal ...
(Date:4/23/2014)... Los Angeles, London (April 23, 2014). "I think one can ... energy pathwayas well as doing everything else that we canthen ... says Tom Wigley, one of the world,s foremost climate researchers, ... Scientists , published by SAGE. Refusing to take significant action ... will eventually be needed to address the problem, Wigley explains ...
(Date:4/22/2014)... team of Yale researchers will lead a five-year, $3 ... rain events is affecting the transport of dissolved organic ... they say could alter the chemical composition and water ... With funding from the National Science Foundation,s MacroSystems Biology ... across the watershed, which begins in Canada and runs ...
Breaking Biology News(10 mins):Ravens understand the relations among others 2Is nuclear power the only way to avoid geoengineering? 2Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3
... specialized sensory organ that the malaria mosquito uses to ... of researchers has taken an important step toward developing ... used to reduce the threat of malaria, generally considered ... sensory organ is the maxillary palp. It is one ...
... at St. Jude Childrens Research Hospital provide strong evidence ... which has revolutionized the treatment of chronic myelogenous leukemia, ... particularly aggressive form of acute lymphoblastic leukemia (ALL). Targeted ... a specific molecule, a strategy aimed at making treatments ...
... may be attracted to more than the bananas that are ... carbonated water. Fruit flies detect and are attracted to the ... found on rotting fruits containing yeast, concludes a study appearing ... at the University of California, Berkeley, who conducted the study, ...
Cached Biology News:Advance in effort to fight malaria by tricking the mosquito's sense of smell 2Advance in effort to fight malaria by tricking the mosquito's sense of smell 3St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia 2Researchers find new taste in fruit flies: carbonated water 2Researchers find new taste in fruit flies: carbonated water 3
pH-dependent fluorescence; Maximum intensity observed in basic solutions....
Mouse Anti-Human Kallikrein 2 (Hk2)...
Recognizes a full-length CLC-2 voltage-gated Cl- protein and not with other known proteins tested so far....
... Rabbit polyclonal to ErbB 2 ... Abpromise for all tested applications). ... peptide: AENPEYLGLDVPV conjugated to KLH, corresponding ... of Human c-ErbB2 ...
Biology Products: